HomeCompareADXSD vs BTI

ADXSD vs BTI: Dividend Comparison 2026

ADXSD yields 51.95% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADXSD wins by $397.7K in total portfolio value
10 years
ADXSD
ADXSD
● Live price
51.95%
Share price
$3.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$435.5K
Annual income
$90,970.08
Full ADXSD calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ADXSD vs BTI

📍 ADXSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADXSDBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADXSD + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADXSD pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADXSD
Annual income on $10K today (after 15% tax)
$4,415.58/yr
After 10yr DRIP, annual income (after tax)
$77,324.57/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ADXSD beats the other by $74,955.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADXSD + BTI for your $10,000?

ADXSD: 50%BTI: 50%
100% BTI50/50100% ADXSD
Portfolio after 10yr
$236.6K
Annual income
$46,878.36/yr
Blended yield
19.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ADXSD
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADXSD buys
0
BTI buys
0
No recent congressional trades found for ADXSD or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADXSDBTI
Forward yield51.95%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$435.5K$37.7K
Annual income after 10y$90,970.08$2,786.64
Total dividends collected$350.5K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ADXSD vs BTI ($10,000, DRIP)

YearADXSD PortfolioADXSD Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$15,895$5,194.81$11,299$598.92+$4.6KADXSD
2$24,724$7,716.86$12,794$703.91+$11.9KADXSD
3$37,673$11,218.27$14,518$829.07+$23.2KADXSD
4$56,286$15,975.38$16,513$978.64+$39.8KADXSD
5$82,532$22,306.57$18,827$1,157.84+$63.7KADXSD
6$118,878$30,568.54$21,518$1,373.12+$97.4KADXSD
7$168,350$41,149.89$24,657$1,632.46+$143.7KADXSD
8$234,596$54,462.14$28,329$1,945.74+$206.3KADXSD
9$321,946$70,928.36$32,637$2,325.33+$289.3KADXSD
10$435,453$90,970.08$37,708$2,786.64+$397.7KADXSD

ADXSD vs BTI: Complete Analysis 2026

ADXSDStock

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

Full ADXSD Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ADXSD vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADXSD vs SCHDADXSD vs JEPIADXSD vs OADXSD vs KOADXSD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.